Azurity Loses Hypertension Drug Patent Trial Against Alkem

Azurity Loses Hypertension Drug Patent Trial Against Alkem

Source Node: 1956223
By Ryan Davis (February 13, 2023, 10:00 PM EST) — A federal judge sitting in Delaware ruled Friday that several claims of two patents on Azurity Pharmaceuticals Inc.’s hypertension drug Epaned are invalid, handing a win to Alkem Laboratories Ltd., which is planning a generic version of the drug….

Time Stamp:

More from Law 360